Patents Assigned to Yeda Research and Development Co., Ltd.
-
Publication number: 20220242838Abstract: This invention is directed to a method of oxidation of 5-chloro-2-((3,4,4-trifluorobut-3-en-1-yl)thio)-1?3,3?2-thiazole and analogs thereof to the corresponding sulfone, using an oxidant and a metal oxide-based catalyst.Type: ApplicationFiled: August 4, 2020Publication date: August 4, 2022Applicant: YEDA RESEARCH AND DEVELOPMENT CO.LTD.Inventors: Ronny NEUMANN, Alexander KHENKIN
-
Publication number: 20220241331Abstract: A method of treating cancer in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of T cells expressing a T cell receptor (TCR) having a CDR3 amino acid sequence selected from the group consisting of 199-210.Type: ApplicationFiled: May 19, 2020Publication date: August 4, 2022Applicant: Yeda Research and Development Co. Ltd.Inventors: Yardena SAMUELS, Shelly KALAORA, Aviyah PERI, Nir FRIEDMAN, Shlomit REICH-ZELIGER, Erez GREENSTEIN
-
Patent number: 11400156Abstract: A method of treating or preventing a disease associated with a secondary infection in a subject infected with a pathogen is provided. The method comprises administering to the subject a therapeutically effective amount of an anti-pathogenic agent directed towards the pathogen and a therapeutically effective amount of an agent which down-regulates at least one extracellular matrix-associated polypeptide.Type: GrantFiled: March 26, 2020Date of Patent: August 2, 2022Assignee: Yeda Research and Development Co. Ltd.Inventors: Irit Sagi, Dalit Talmi-Frank, Inna Solomonov, Ido Amit
-
Publication number: 20220236356Abstract: Method for mapping the transverse relaxation times (T2) in a magnetic resonance imaging (MRI) scan defined over a plurality of pixels, where each pixel is associated with a multicomponent T2 (mcT2) signal, comprises: accessing a computer readable medium storing an mcT2 dictionary having a set of synthetic mcT2 signals, and selecting a subset of synthetic mcT2 signals for which correlations between the synthetic mcT2 signals and pixels in the MRI scan are highest among the set. For each of at least a portion of the pixels, a respective mcT2 scan signal is fitted to the subset to provide, a plurality of T2 values for the pixel. A T2 map of the MRI scan is generated based on the T2 values.Type: ApplicationFiled: January 27, 2022Publication date: July 28, 2022Applicants: Ramot at Tel-Aviv University Ltd., Yeda Research and Development Co. Ltd.Inventors: Noam BEN-ELIEZER, Noam OMER, Meirav GALUN
-
Publication number: 20220235262Abstract: This invention relates to materials and to films comprising molecular photoswitches. The films exhibit excellent photoswitchable properties in the dry state. This invention is also related to processes of making the materials and the films and to uses of the films. The invention also relates to devices and systems comprising the films of this invention.Type: ApplicationFiled: April 14, 2020Publication date: July 28, 2022Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Rafal KLAJN, Zonglin CHU
-
Publication number: 20220236257Abstract: The disclosure presented herein provides artificial receptors and a system comprising recombinant cells decorated with various labels and/or synthetic agents, wherein said labels and/or synthetic agents can be reversibly modified or removed from the cells. Also disclosed herein are methods for decorating and/or modifying the cells and methods for using thereof.Type: ApplicationFiled: June 5, 2019Publication date: July 28, 2022Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: David MARGULIES, Leila MOTIEI, Naama LAHAV
-
Patent number: 11396012Abstract: A microfluidic device is disclosed which comprises: (i) at least one reaction unit having a test chamber connected to at least one microchannel, wherein a surface of at least a portion of said reaction unit is attached to an isolated nucleic acid; and (ii) a flow-through channel having at least one inlet port and at least one outlet port, said flow-through channel and said microchannel being of dimensions to allow reactant diffusion to and from said reaction unit, wherein the diffusion time of said reactant along the microchannel is shorter than the flow time along the microchannel.Type: GrantFiled: October 7, 2014Date of Patent: July 26, 2022Assignee: Yeda Research and Development Co. Ltd.Inventors: Roy Bar-Ziv, Eyal Karzbrun, Alexandra Tayar
-
Patent number: 11395590Abstract: A method of transcranial brain optical imaging including obtaining a Laser Speckle (LS) image of cranial blood vessels of a subject, obtaining a Dynamic Fluorescence (DF) image of the cranial blood vessels of the subject, and combining the LS image and the DF image producing a combined color image which displays both structure of the cranial blood vessels and perfusion of blood along the cranial blood vessels. Related apparatus and methods are also described.Type: GrantFiled: April 30, 2015Date of Patent: July 26, 2022Assignees: Yeda Research and Development Co. Ltd., Ministry of Health on behalf of The Jerusalem Mental Health CenterInventors: Alon Harmelin, David Israeli, Yuri Kuznetsov, Vyacheslav Kalchenko
-
Patent number: 11396563Abstract: A polymeric compound is disclosed herein, having the general formula I: wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.Type: GrantFiled: July 2, 2020Date of Patent: July 26, 2022Assignee: Yeda Research and Development Co. Ltd.Inventors: Jacob Klein, Weifeng Lin, Ronit Goldberg
-
Publication number: 20220220559Abstract: A method of prognosing a course of disease progression and/or survival time in a subject diagnosed with ALS or FTD is disclosed. The method comprising: (a) detecting a level of miR-181 in a biological sample of the subject; and (b) determining the disease progression and/or survival time based on the level of the miR-181, wherein: (i) when the level of miR-181 is higher than that in a control sample, it is indicative of a rapid disease progression and/or poor survival; or (ii) when the level of miR-181 is about the same or lower than that in the control sample, it is indicative of a slow disease progression and/or good survival. Methods of prognosing a stage of disease in a subject diagnosed with ALS or FTD are also disclosed.Type: ApplicationFiled: May 13, 2020Publication date: July 14, 2022Applicants: Yeda Research And Development Co. Ltd., Queen Mary University London, UCL Business LtdInventors: Eran HORNSTEIN, Iddo MAGEN, Andrea MALASPINA, Pietro FRATTA
-
Publication number: 20220217934Abstract: Provided herein are genetically modified cells and genetically modified plants having increased or decreased expression of a cellulose synthase like G (CSLG) enzyme. These cells and plants may have an increased or decreased content a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin, compared to a corresponding unmodified cell or plant. Also provided herein are methods of producing a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin in a genetically modified cell, as well as methods of reducing the content of a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin in a cell of a plant or a plant part, and methods of increasing the content of a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin in a cell of a plant or a plant part.Type: ApplicationFiled: September 5, 2019Publication date: July 14, 2022Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Asaph AHARONI, Prashant SONAWANE, Maxim ITKIN, Adam JOZWlAK
-
Patent number: 11385242Abstract: Provided is a composition including a combination of at least one short peptide and at least one peptide dimer, in defined ratio, to which autoantibodies found in elevated levels in schizophrenic patients bind.Type: GrantFiled: July 14, 2016Date of Patent: July 12, 2022Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Meir Shinitzky, Ludmila Schechtman
-
Publication number: 20220211758Abstract: The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen.Type: ApplicationFiled: January 13, 2022Publication date: July 7, 2022Applicant: Yeda Research and Development Co. Ltd.Inventors: Rachel Lea EISENBACH, Yosi GOZLAN, Esther TZEHOVAL
-
Publication number: 20220213467Abstract: A method of assembling and immobilizing proteinaceous complexes is disclosed. In addition, methods of generating functional RNA polymerase and ribosomal subunits are disclosed.Type: ApplicationFiled: March 24, 2022Publication date: July 7, 2022Applicant: Yeda Research and Development Co. Ltd.Inventors: Roy BAR-ZIV, Shirley SHULMAN DAUBE, Michael LEVY, Reuven FALKOVICH, Ohad VONSHAK, Yiftach DIVON
-
Patent number: 11368670Abstract: A multi-layer viewing system includes a stationary imager and a beam projector to project physical layer markings onto a region of an object. A headset includes an augmented reality display that is sufficiently transparent to enable a user who is wearing the headset to directly view the object through the display, and to display annotation that is superimposed on the object. A processor is configured to receive a selected location relative to the target for display of the annotation, determine an orientation of the augmented reality display by identifying images of markings in acquired images or markings on the object, calculate a display location for displaying the annotation on the augmented reality display such that the annotation is perceivable by the user as displayed at the selected position, and display the annotation at the calculated display location.Type: GrantFiled: October 25, 2018Date of Patent: June 21, 2022Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Shimon Ullman, Daniel Harari, Liav Assif, Igal Koifman
-
Publication number: 20220184148Abstract: A method of determining tolerance to an agent in a healthy subject is disclosed. The method comprises: (a) determining a signature of a microbiome in a sample of the healthy subject who has been subjected to the agent or condition; and (b) comparing the signature of the microbiome of the healthy subject to at least one reference signature of a pathological microbiome, wherein when the signature of the microbiome of the healthy subject is statistically significantly similar to the reference signature of the pathological microbiome, it is indicative that the healthy subject is intolerant to the agent.Type: ApplicationFiled: January 20, 2022Publication date: June 16, 2022Applicant: Yeda Research and Development Co. Ltd.Inventors: Eran ELINAV, Eran SEGAL
-
Publication number: 20220184154Abstract: A method of treating bacterial vaginosis in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a composition which comprises between three and twenty species of bacteria or a secretion thereof, wherein at least 70% of the bacteria of the composition are of the species Lactobacillus crispatus, thereby treating the bacterial vaginosis.Type: ApplicationFiled: February 28, 2022Publication date: June 16, 2022Applicants: Yeda Research and Development Co. Ltd., Hadasit Medical Research Services and Development Ltd.Inventors: Eran ELINAV, Yotam COHEN, Ahinoam LEV-SAGIE, Debra GOLDMAN-WOHL
-
Publication number: 20220175807Abstract: Disclosed herein are prokaryotic homologs of viperin (pVips), and nucleotide and nucleoside analogs produced from pVips. These nucleotide and nucleoside analogs stop nucleotide chain synthesis and provide host cells with resistance to viral infections by targeting actively replicating viral genome. Further, these nucleotide and nucleoside analogs decrease DNA replication in malignant cells. Further disclosed are methods of identifying pVips, and nucleotide and nucleoside analogs produced thereof.Type: ApplicationFiled: March 29, 2020Publication date: June 9, 2022Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Rotem SOREK, Auda BERNHEIM, Adl Jenny MILLMAN DAYAN
-
Publication number: 20220170939Abstract: A method of selecting a treatment for a subject having cancer is disclosed. The method comprises: (a) determining a level of catalytic activity of at least one DNA repair enzyme in a biological sample of the subject; and (b) selecting an immune checkpoint regulator as a treatment for a subject having a statistically significant different level of catalytic activity of said DNA repair enzyme as compared to the catalytic activity of said DNA repair enzyme in a biological sample of a healthy subject.Type: ApplicationFiled: February 13, 2022Publication date: June 2, 2022Applicant: Yeda Research and Development Co. Ltd.Inventors: Zvi LIVNEH, Tamar PAZ-ELIZUR
-
Publication number: 20220170039Abstract: The present invention provides compositions for attenuating the function of atypical CYS HIS rich thioredoxin 4 (ACHT4), a light-regulated protein expressed in plants and algae that controls starch storage in chloroplast, and methods for increasing plant and algae growth and yield.Type: ApplicationFiled: February 21, 2022Publication date: June 2, 2022Applicant: Yeda Research and Development Co. Ltd.Inventors: Avihai DANON, Erez ELIYAHU, Vivekanand TIWARI